Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

Cited by (719)

Items 101–200 of 719

1. Promises and challenges: cabotegravir for preexposure prophylaxis
   Matthew A. Spinelli, Beatriz Gilda Jegerhorn Grinsztejn, Raphael J. Landovitz · 2022 · Current Opinion in HIV and AIDS
2. Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study
   Bernard Surial, Bruno Ledergerber, Alexandra Calmy, Matthias L. Cavassini, Huldrych F. Günthard, Helen Kovari, M Stöckle, Enos Bernasconi, Patrick Schmid, Christoph A. Fux et al. · 2020 · The Journal of Infectious Diseases
3. Cardiovascular disease in HIV patients: recent advances in predicting and managing risk
   Pádraig McGettrick, Patrick W. G. Mallon, Caroline Anne Sabin · 2020 · Expert Review of Anti-infective Therapy
4. Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic
   Toby Pepperrell, Andrew Martin Hill, Michelle A. Moorhouse, Polly Clayden, Kaitlyn McCann, Simiso Mandisa Sokhela, Celicia M. Serenata, François Venter · 2020 · Journal of Virus Eradication
5. Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus
   Emma M. Kileel, Janet Lo, Carlos Malvestutto, Kathleen V. Fitch, Markella V. Zanni, Carl J. Fichtenbaum, Edgar Turner Overton, Nwora Lance Okeke, Princy N. Kumar, Esau Custodio Joao et al. · 2021 · Open Forum Infectious Diseases
6. Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Naïve and Switch Scenarios in HIV-Infected Patients
   María Saumoy, José Luis Sánchez‐Quesada, Jordi Ordóñez‐Llanos, Daniel Podzamczer · 2021 · Journal of Clinical Medicine
7. HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells
   Martine Auclair, Anne-Claire Guénantin, Soraya Fellahi, Marie Garcia, Jacqueline Capeau · 2020 · PLoS ONE
8. Integrase Strand-Transfer Inhibitor Use and Cardiovascular Events in Adults with HIV: An Emulation of Target Trials in the HIV-CAUSAL and ART-CC Collaborations
   Sophia M. Rein, Sara Lodi, Roger W Logan, Giota Touloumi, Anastasia Antoniadou, Linda Wittkop, Fabrice Bonnet, Ard van Sighem, Marc van der Valk, Peter Reiss et al. · 2023 · The Lancet HIV
9. Emergence of Acquired Dolutegravir Resistance in Treatment-experienced People With HIV in Lesotho
   Nadine Tschumi, Blaise Lukau, Katleho Tlali, Lipontso Motaboli, Mpho Kao, Mathebe Kopo, Kathrin Haenggi, Moleboheng Mokebe, Klaudia Naegele, Irene Ayakaka et al. · 2024 · Clinical Infectious Diseases
10. Models of service delivery for optimizing a patient’s first six months on antiretroviral therapy for HIV: an applied research agenda
    Sydney B. Rosen, Anna Grimsrud, Peter D Ehrenkranz, Ingrid Theresa Katz · 2020 · Gates Open Research
11. Sex Differences in Non-AIDS Comorbidities Among People With Human Immunodeficiency Virus
    Renee A Pond, Lauren Frances Collins, Cecile Delille Lahiri · 2021 · Open Forum Infectious Diseases
12. Tenofovir alafenamide nephrotoxicity: a case report and literature review
    Thornthun Ueaphongsukkit, Sivaporn Gatechompol, Anchalee Avihingsanon, Jerasit Surintrspanont, Kroonpong Iampenkhae, Yingyos Avihingsanon, Suwasin Udomkarnjananun · 2021 · AIDS Research and Therapy
13. Second-Line Switch to Dolutegravir for Treatment of HIV Infection
    Loice Achieng Ombajo, Jeremy A Penner, Joseph Nkuranga, Jared Ongechi Mecha, Margaret Mburu, Collins Ojwang' Odhiambo, Florentius Ndinya, Rukia Aksam, Richard Njenga, Simon Wahome et al. · 2023 · New England Journal of Medicine
14. Adults with Perinatally Acquired HIV; Emerging Clinical Outcomes and Data Gaps
    Merle Henderson, Sarah J. Fidler, Caroline Foster · 2024 · Tropical Medicine and Infectious Disease
15. Potential role of the melanocortin signaling system interference in the excess weight gain associated to some antiretroviral drugs in people living with HIV
    Peré Domingo, Francesc Villarroya, Marta Giralt, Joan Carles Domingo · 2020 · International Journal of Obesity
16. Tenofovir alafenamide use in pregnant and lactating women living with HIV
    Ahizechukwu Chigoziem Eke, Kristina M. Brooks, Rahel Demissew Gebreyohannes, Jeanne S. Sheffield, Kelly E. Dooley, Mark H. Mirochnick · 2020 · Expert Opinion on Drug Metabolism & Toxicology
17. Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV
    Cecile Delille Lahiri, Yanxun Xu, Kunbo Wang, Jessica A. Alvarez, Anandi N. Sheth, Jane A. O’Halloran, Amanda B. Spence, Phyllis C. Tien, Deborah Gustafson, Joel E. Milam et al. · 2020 · AIDS Research and Human Retroviruses
18. Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study
    Jean Andre Van Wyk, Mounir Ait‐Khaled, Jesús Santos, Stefan Scholten, Michael B. Wohlfeiler, Faïza Ajana, Bryn Jones, Maria‐Claudia Nascimento, Allan R. Tenorio, Don E. Smith et al. · 2021 · JAIDS Journal of Acquired Immune Deficiency Syndromes
19. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial
    Nathalie De Castro, Olivier Marcy, Corine Chazallon, Eugène Messou, Serge Paul Eholié, Jean-Baptiste N'takpe, Nilesh Bhatt, Celso Khosa, Isabel Massango, Didier Laureillard et al. · 2021 · The Lancet Infectious Diseases
20. Redefining therapeutic success in HIV patients: an expert view
    Antonio Antela, Antonio Rivero, Josep Maria Llibre, Santiago Moreno, the RET Group, Antonio Antela, Josep M Llibre, Santiago Moreno, Antonio Rivero, Marta Montero et al. · 2021 · Journal of Antimicrobial Chemotherapy
21. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV
    P Plum, Nathalie Maes, Anne-Sophie Sauvage, Frédéric Frippiat, Christelle Meuris, Françoise Uurlings, Marianne Lecomte, Philippe Léonard, Nicolas Paquot, Karine Fombellida et al. · 2021 · BMC Infectious Diseases
22. Obesity in young South African women living with HIV: A cross-sectional analysis of risk factors for cardiovascular disease
    Sherika Hanley, Dhayendre Moodley, Mergan Naidoo · 2021 · PLoS ONE
23. Weight Gain Among Treatment-Naïve Persons With HIV Receiving Dolutegravir in Kenya
    Kassem Bourgi, Susan Ofner, Beverly Sue Musick, Bradley Griffith, Lameck Oteko Diero, Kara Wools‐Kaloustian, Constantin Theodore Yiannoutsos, Samir Kumar Gupta · 2022 · JAIDS Journal of Acquired Immune Deficiency Syndromes
24. Biktarvy for the treatment of HIV infection: Progress and prospects
    Erik De Clercq, Zhenlan Zhang, Jie Huang, Min Zhang, Guangdi Li · 2023 · Biochemical Pharmacology
25. Innovative Approaches for Pharmacology Studies in Pregnant and Lactating Women: A Viewpoint and Lessons from HIV
    Ahizechukwu Chigoziem Eke, Adeniyi Olagunju, Brookie M. Best, Mark H. Mirochnick, Jeremiah D. Momper, Elaine J. Abrams, Martina Penazzato, Tim Roy Cressey, Angela P. H. Colbers · 2020 · Clinical Pharmacokinetics
26. Clinical Features and Outcomes of Coronavirus Disease 2019 Among People With Human Immunodeficiency Virus in the United States: A Multicenter Study From a Large Global Health Research Network (TriNetX)
    George A. Yendewa, Jaime Abraham Perez, Kayla Schlick, Heather Tribout, Grace A. McComsey · 2021 · Open Forum Infectious Diseases
27. Prevalence and Risk Factors of Moderate-to-Severe Hepatic Steatosis in Human Immunodeficiency Virus Infection: The Copenhagen Co-morbidity Liver Study
    Ditte Marie Kirkegaard-Klitbo, Andreas Fuchs, Stefan Stender, Per Ejlstrup Sigvardsen, Jørgen Tobias Kühl, Klaus Fuglsang Kofoed, Lars Køber, Børge Grønne Nordestgaard, Flemming Bendtsen, Amanda Mocroft et al. · 2020 · The Journal of Infectious Diseases
28. Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV
    Giovanni Guaraldi, Stefano Calza, Jovana Milić, Andrea Calcagno, Emanuele Focà, Matteo Rota, Stefano Renzetti, Anna Celotti, Matteo Siano, Benedetto Maurizio Celesia et al. · 2021 · AIDS
29. Dolutegravir Resistance in Malawi’s National HIV Treatment Program
    Joep J. van Oosterhout, Chifundo Chipungu, Lyse Nkhoma, Hope Kanise, Mina C. Hosseinipour, Jean-Batiste Sagno, Katherine Simon, Carrie M. Cox, Risa M. Hoffman, Kim Steegen et al. · 2022 · Open Forum Infectious Diseases
30. Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study
    Javier Martínez‐Sanz, Sergio Serrano Villar, Alfonso Muriel, Lucio Jesus García-Fraile, Eva Orviz, Álvaro Mena de, Antoni A Campins, Santiago Moreno · 2022 · Clinical Infectious Diseases
31. Diabetes in HIV: the Link to Weight Gain
    Samuel S. Bailin, John Robert Koethe · 2022 · Current HIV/AIDS Reports
32. IFIH1 (MDA5) is required for innate immune detection of intron-containing RNA expressed from the HIV-1 provirus
    Mehmet Hakan Guney, Karthika Nagalekshmi, Sean Matthew McCauley, Claudia Carbone, Özkan Aydemir, Jeremy Luban · 2024 · Proceedings of the National Academy of Sciences
33. Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment
    Aditya N. Bade, JoEllyn McMillan, Yutong Liu, Benson Edagwa, Howard Eliot Gendelman · 2021 · Molecular Neurobiology
34. Maternal weight and birth outcomes among women on antiretroviral treatment from conception in a birth surveillance study in Botswana
    Rebecca Zash, Ellen C. Caniglia, Modiegi Diseko, Gloria Katuta Mayondi, Judith Mabuta, Rebecca L. Luckett, George Justus Hofmeyr, Chelsea Morroni, Doreen Ramogola‐Masire, Paige L. Williams et al. · 2021 · Journal of the International AIDS Society
35. Evidence gaps on weight gain in people living with HIV: a scoping review to define a research agenda
    Giovanni Guaraldi, Paolo Bonfanti, Antonio Di Biagio, Andrea Gori, Jovana Milić, Paola Saltini, Francesco Vladimiro Segala, Nicola Squillace, Lucia Taramasso, Antonella Cingolani · 2023 · BMC Infectious Diseases
36. Associations of modern initial antiretroviral therapy regimens with all-cause mortality in people living with HIV in resource-limited settings: a retrospective multicenter cohort study in China
    Xinsheng Wu, Guohui Wu, Ping Ma, Rugang Wang, Linghua Li, Yuanyi Chen, Junjie Xu, Yuwei Li, Quanmin Li, Yuecheng Yang et al. · 2023 · Nature Communications
37. Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir/ritonavir
    Leonardo Calza, Vincenzo Colangeli, Marco Borderi, Isabella Bon, Aurora Borioni, Francesca Volpato, Maria Carla Re, Pierluigi Viale · 2019 · Infection
38. Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration
    Nikos Pantazis, Sophie Grabar, Marc van der Valk, Marc Van der Valk, Inma Jarrín, Ard van Sighem, Laurence Meyer, Christina Carlander, John Gill, Alain Volny Anne et al. · 2024 · The Lancet HIV
39. The impact of sex on HIV immunopathogenesis and therapeutic interventions
    Erin Mihealsick, Anna Word, Eileen P. Scully · 2024 · Journal of Clinical Investigation
40. Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs
    Florence Rodgers, Toby Pepperrell, Sarai Keestra, Victoria Pilkington · 2021 · Trials
41. Antiretroviral therapy in older people with HIV
    Aaron G. Richterman, Paul Edward Sax · 2020 · Current Opinion in HIV and AIDS
42. New Drugs for NASH and HIV Infection: Great Expectations for a Great Need
    Giovanni Guaraldi, James B. Maurice, Catia Marzolini, Kenneth Marc Monteith, Jovana Milić, Emmanuel A. Tsochatzis, Sanjay R. Bhagani, Caryn Gee Morse, Jennifer C. Price, Patrick Ingiliz et al. · 2020 · Hepatology
43. HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study
    Akash Devendra, Maurus Kohler, Motlatsi Letsika, Hape Khooa, Lipontso Motaboli, Malebanye Lerotholi, Nadine Tschumi, Niklaus Daniel Labhardt, Jennifer Anne Brown · 2024 · AIDS
44. Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy
    Shahini Shah, Andrew Martin Hill · 2020 · Current Opinion in Infectious Diseases
45. Weight changes after antiretroviral therapy initiation in CoRIS (Spain): a prospective multicentre cohort study
    Javier Martínez‐Sanz, José Ramón Blanco, Alfonso Muriel, Marı́a Jesús Pérez-Elı́as, Rafael Rubio‐Martín, Juan Berenguer, Joaquim Peraire, Enrique Bernal, Onofre Juan Martínez, Sergio Serrano Villar et al. · 2021 · Journal of the International AIDS Society
46. One in 10 Virally Suppressed Persons With HIV in The Netherlands Experiences ≥10% Weight Gain After Switching to Tenofovir Alafenamide and/or Integrase Strand Transfer Inhibitor
    Myrthe L. Verburgh, Ferdinand W.N.M. Wit, Anders C. Boyd, Sebastiaan O Verboeket, Peter Reiss, Marc van der Valk · 2022 · Open Forum Infectious Diseases
47. 96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients
    Zhihong Liu, Qinglong Jin, Yuexin Zhang, Guozhong Gong, Guicheng Wu, Lvfeng Yao, Xiaofeng Wen, Zhiliang Gao, Yan Huang, Daokun Yang et al. · 2022 · Journal of Clinical and Translational Hepatology
48. Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
    Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, Roberto Ortiz, Anson K Wurapa, Moti N. Ramgopal, Dushyantha T. Jayaweera, Peter A. Leone, Jessica E. Matthews, Michael A. Cupo et al. · 2023 · Open Forum Infectious Diseases
49. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B
    Pin‐Nan Cheng, I‐Che Feng, Jyh-Jou Chen, Hsing‐Tao Kuo, Pei‐Lun Lee, Ming‐Lung Yu, Yen‐Cheng Chiu, Hung‐Chih Chiu, Shih‐Chieh Chien, Pei‐Jer Chen et al. · 2023 · Alimentary Pharmacology & Therapeutics
50. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China
    Danping Liu, Yinzhong Shen, Renfang Zhang, Jingna Xun, Jiangrong Wang, Li Liu, Corklin R. Steinhart, Jun Chen, Hongzhou Lu · 2020 · Journal of Gastroenterology and Hepatology
51. Dyslipidemia among adult people living with HIV on dolutegravir – based antiretroviral therapy at a private tertiary hospital in Kampala, Uganda: burden and determinants
    Vianney John Kigongo, Joaniter Immaculate Nankabirwa, Freddy Eric Kitutu, Ronald Ssenyonga, Ronald Kasoma Mutebi, Andrew Kazibwe, Ronald Kiguba, Andrew Ddungu Kambugu, Barbara Castelnuovo · 2024 · BMC Infectious Diseases
52. Weight Changes With Integrase Strand Transfer Inhibitor Therapy in the Management of HIV Infection: A Systematic Review
    Elizabeth Kelly Hester, Sage B. Greenlee, Spencer H. Durham · 2022 · Annals of Pharmacotherapy
53. Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study
    Bruno Émond, Carmine Rossi, Aurélie Côté‐Sergent, Keith Dunn, Patrick Lefèbvre, Marie- Hélène Lafeuille, Prina Donga · 2021 · Journal of health economics and outcomes research
54. Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis
    Caitlin Prather, Chaeok Jeon · 2022 · American Journal of Health-System Pharmacy
55. HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysis
    Ezéchiel Ngoufack Jagni Semengue, Maria Mercedes Santoro, Valantine Ngum Ndze, Aude Christelle Ka’e, Yagaï Bouba, Alex Durand Nka, Béatrice Dambaya, Désiré Takou, Georges Této, Lavinia Fabeni et al. · 2022 · PLOS Global Public Health
56. Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimens
    Joaquín Burgos, Sergio Moreno‐Fornés, Juliana Reyes‐Urueña, Andreu Bruguera, Raquel Martín-Iguacel, Berta Raventós, Josep Maria Llibre, Arkaitz Imaz, Joaquim Peraire, A. Ortí et al. · 2022 · Journal of Antimicrobial Chemotherapy
57. Use of Tenofovir Alafenamide Fumarate for HIV Pre-Exposure Prophylaxis and Incidence of Hypertension and Initiation of Statins
    Adovich S. Rivera, Katherine J. Pak, Matthew T. Mefford, Rulin C. Hechter · 2023 · JAMA Network Open
58. Exercise to Prevent Accelerated Vascular Aging in People Living With HIV
    Raymond Jones, Austin T. Robinson, Lauren Brittany Beach, Merry L. Lindsey, Annet Kirabo, Antentor Othrell Hinton Jr., Kristine Mace Erlandson, Nathaniel D.M. Jenkins · 2024 · Circulation Research
59. Sex Differences in the Treatment of HIV
    Jennifer Cohn, Julie A. Ake, Michelle A. Moorhouse, Catherine C. Godfrey · 2020 · Current HIV/AIDS Reports
60. Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial
    Cissy M Kityo, Ivan Mambule, Joseph Musaazi, Simiso Mandisa Sokhela, Henry Mugerwa, Ibrahim Yawe, Fiona V Cresswell, Abraham Mosigisi Siika, Josphat Kosgei, Reena Shah et al. · 2025 · Nature Medicine
61. Weight Gain in Incarcerated Individuals Living With HIV After Switching to Integrase Strand Inhibitor-Based Therapy
    Rachel N. Goldberg, Alexandra T. Kania, Sarah M. Michienzi, Mahesh C. Patel, Melissa E. Badowski · 2021 · Journal of the International Association of Providers of AIDS Care (JIAPAC)
62. Integrase Strand Transfer Inhibitors and Weight Gain in Children and Youth With Perinatal Human Immunodeficiency Virus in the DC Cohort
    Wei Li Adeline Koay, Sahera Dirajlal‐Fargo, Matthew E. Levy, Paige E. Kulie, Anne Kress Monroe, Amanda Derryck Castel, Natella Yurievna Rakhmanina, Lawrence J. D’Angelo, Natella Yurievna Rakhmanina, Michael Kharfen et al. · 2021 · Open Forum Infectious Diseases
63. Prevalence and Characteristics of HIV-Associated Stroke in a Tertiary Hospital Setting in South Africa
    Craig Corbett, Naeem Brey, Richard Pitcher, Suzanne O’Hagan, Tonya M. Esterhuizen, Felicia C. Chow, Eric H. Decloedt · 2022 · Neurology
64. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study
    Adam Trickey, Lei Zhang, Michael John Gill, Fabrice Bonnet, Greer Burkholder, Antonella Castagna, Matthias L. Cavassini, Piotr Cichon, Heidi M. Crane, Peré Domingo et al. · 2022 · The Lancet HIV
65. Striking differences in weight gain after cART initiation depending on early or advanced presentation: results from the ANRS CO4 FHDH cohort
    Sophie Grabar, Valérie Potard, Lionel Piroth, Sophie Abgrall, Louis Bernard, Clotilde Allavena, Fabienne Caby, Pierre de Truchis, Claudine Duvivier, Patricia Enel et al. · 2023 · Journal of Antimicrobial Chemotherapy
66. Contribution of Low CD4 Cell Counts and High Human Immunodeficiency Virus (HIV) Viral Load to the Efficacy of Preferred First-Line Antiretroviral Regimens for Treating HIV Infection: A Systematic Review and Meta-Analysis
    José Antonio Pérez-Molina, Clara Crespillo‐Andújar, Javier Zamora, Borja Manuel Fernandez-Felix, Andrea Gaetano Gil, Juan Carlos López Bernaldo de Quirós, Sergio Serrano Villar, Santiago Moreno, Noelia Álvarez Díaz, Juan Berenguer · 2023 · Clinical Infectious Diseases
67. Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96
    Bin Su, Guiju Gao, Min Wang, Yanqiu Lu, Linghua Li, Chen Chen, Yuanyuan Chen, Chuan Song, Fengting Yu, Yixin Liu et al. · 2023 · The Lancet Regional Health - Western Pacific
68. Body weight and blood pressure changes on dolutegravir‐, efavirenz‐ or atazanavir‐based antiretroviral therapy in Zimbabwe: a longitudinal study
    Tinei Shamu, Matthias Egger, Tinashe Mudzviti, Cleophas Chimbetete, Justen Manasa, Nanina Anderegg · 2024 · Journal of the International AIDS Society
69. Cardiovascular disease risk in an urban African population: a cross-sectional analysis on the role of HIV and antiretroviral treatment
    Alinda G. Vos, Klariska Hoeve, Roos E. Barth, Joyce Peper, Michelle A. Moorhouse, Nigel John Crowther, François Venter, Diederick E. Grobbee, Michiel L. Bots, Kerstin Klipstein‐Grobusch · 2019 · Retrovirology
70. Super learner analysis of real‐time electronically monitored adherence to antiretroviral therapy under constrained optimization and comparison to non‐differentiated care approaches for persons living with HIV in rural Uganda
    Alejandra Benitez, Nicholas Musinguzi, David R. Bangsberg, Mwebesa Bwana, Conrad K. Muzoora, Peter W. Hunt, Jeffrey N. Martin, Jessica Elizabeth Haberer, Maya L. Petersen · 2020 · Journal of the International AIDS Society
71. The Current State of HIV and Aging: Findings Presented at the 10th International Workshop on HIV and Aging
    Stephanie Shiau, Alexis Anne Bender, Jane A. O’Halloran, Erin E. Sundermann, Juhi Aggarwal, Keri N. Althoff, Jason V. Baker, Steven G. Deeks, Linda P. Fried, Stephen E. Karpiak et al. · 2020 · AIDS Research and Human Retroviruses
72. Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG
    Fowzia Ibrahim, Amanda Samarawickrama, Lisa Hamzah, Rachel Vincent, Yvonne C. Gilleece, Laura Jane Waters, Stephen Kegg, Birgit Barbini, Lucy J. Campbell, Frank A. Post et al. · 2020 · HIV Medicine
73. Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV‐1‐infected patients: a real‐world study in Japan
    Naoki Kanda, Koh Okamoto, Hisatoshi Okumura, Makiko Mieno, Kentaro Sakashita, Teppei Sasahara, Shuji Hatakeyama · 2021 · HIV Medicine
74. Cardiometabolic Complications in Youth With Perinatally Acquired HIV in the Era of Antiretroviral Therapy
    Sahera Dirajlal‐Fargo, Grace A. McComsey · 2021 · Current HIV/AIDS Reports
75. Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency Virus
    Zinhle Cindi, Aida N. Kawuma, Gary Maartens, Yuki Bradford, François Venter, Simiso Mandisa Sokhela, Nomathemba C. Chandiwana, Roeland E. Wasmann, Paolo Denti, Lubbe Wiesner et al. · 2022 · The Journal of Infectious Diseases
76. HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment
    Emma G. Foster, Howard Eliot Gendelman, Aditya N. Bade · 2022 · Pharmaceuticals
77. Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa
    Nomathemba C. Chandiwana, Matthew Chersich, François Venter, Godspower Akpomiemie, Andrew Martin Hill, Bryony Simmons, Shahin Lockman, Celicia M. Serenata, Lee Fairlie, Michelle A. Moorhouse · 2020 · AIDS
78. Making a COVID-19 vaccine that works for everyone: ensuring equity and inclusivity in clinical trials
    Toby Pepperrell, Florence Rodgers, Pranav Tandon, Kelly Sarsfield, Molly Pugh-Jones, Theo Rashid, Sarai Keestra · 2021 · Global Health Action
79. “It’s only fatness, it doesn’t kill”: a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda
    Yussif Nagumse Alhassan, Adelline Twimukye, Thokozile Rosemary Malaba, Landon Myer, Catriona John Waitt, Mohammed Lamorde, Angela P. H. Colbers, Helen E. Reynolds, Saye Khoo, Miriam Taegtmeyer · 2022 · BMC Women s Health
80. Metabolic Complications After Initiating BIC/FTC/TAF Versus DTG + 3TC in Antiretroviral-therapy-naive Adults With HIV: A Multicenter Prospective Cohort Study
    Alejandro García García, Miguel Suárez Robles, Marı́a Jesús Pérez-Elı́as, Eugènia Negredo, José Alcamı́, Carmen Elena Gómez Rodríguez, Patricia González‐Ruano, Miguel Alberto de Zárraga Fernández, Carlos Dueñas Gutiérrez, Santiago Moreno et al. · 2024 · Clinical Infectious Diseases
81. Point-of-Care Tenofovir Urine Testing for the Prediction of Treatment Failure and Drug Resistance During Initial Treatment for Human Immunodeficiency Virus Type 1 (HIV-1) Infection
    Lucas E. Hermans, Chijioke N. Umunnakwe, Samanta Tresha Lalla‐Edward, Shane Hebel, Hugo A. Tempelman, Monique Nijhuis, François Venter, Annemarie M. J. Wensing · 2022 · Clinical Infectious Diseases
82. Adipose Tissue Dysfunction and Energy Balance Paradigms in People Living With HIV
    Claudia E. Ramirez, Neeti Agarwal, Aaron R. Cox, Sean Michael Hartig, Jordan E. Lake, Ashok Balasubramanyam · 2023 · Endocrine Reviews
83. The pathogenesis of obesity in people living with HIV
    Samuel S. Bailin, John Robert Koethe, Peter F. Rebeiro · 2023 · Current Opinion in HIV and AIDS
84. Long-acting antiretroviral therapy effectiveness and patient satisfaction using patient questionnaires: data from a real-world setting
    Keiji Konishi, Daisuke Onozuka, Moeka Okubo, Yu Kasamatsu, Satoshi Kutsuna, Michinori Shirano · 2024 · BMC Infectious Diseases
85. Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data
    Alexander E Rock, Jeremy Lerner, Melissa E. Badowski · 2020 · HIV/AIDS - Research and Palliative Care
86. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz
    Sumbul Asif, Evangelia Baxevanidi, Andrew Martin Hill, François Venter, Lee Fairlie, Masebole S. Masenya, Celicia M. Serenata, Simiso Mandisa Sokhela, Nomathemba C. Chandiwana · 2021 · AIDS
87. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States
    Bruno Émond, Carmine Rossi, Aurélie Côté‐Sergent, Brahim Bookhart, David Anderson, Patrick Lefèbvre, Marie‐Hélène Lafeuille, Prina Z Donga · 2021 · Current Medical Research and Opinion
88. Concentration–response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy
    Rulan Griesel, Aida N. Kawuma, Roeland E. Wasmann, Simiso Mandisa Sokhela, Godspower Akpomiemie, François Venter, Lubbe Wiesner, Paolo Denti, Phumla Sinxadi, Gary Maartens · 2021 · British Journal of Clinical Pharmacology
89. Comparison of Renal Function Biomarkers of Serum Creatinine and Cystatin C in HIV-Infected People on Dolutegravir-Containing Therapy
    Lianfeng Lu, Xiaodi Li, Xiaosheng Liu, Yang Han, Zhifeng Qiu, Xiaojing Song, Yanling Li, Xiaoxia Li, Wei Cao, Taisheng Li · 2022 · Infection and Drug Resistance
90. Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model
    Angelica Perna, Maria Aurora Carleo, Silvia Mascolo, Alessandra Guida, Marcella Contieri, Carmine Sellitto, Eleonora Hay, Paolo De Blasiis, Angela Lucariello, Germano Guerra et al. · 2022 · AIDS
91. Weight and Metabolic Outcomes in Naïve HIV Patients Treated with Integrase Inhibitor-Based Antiretroviral Therapy: A Systematic Review and Meta-Analysis
    Germán Valenzuela-Rodríguez, Carlos Diaz‐Arocutipa, Jaime A. Collins, Adrián Vladimir Hernández · 2023 · Journal of Clinical Medicine
92. Risks of metabolic syndrome in the ADVANCE and NAMSAL trials
    Tamara Tovar Sanchez, Mireille Mpoudi-Etame, Charles Kouanfack, Éric Delaporte, Alexandra Calmy, François Venter, Simiso Mandisa Sokhela, Bronwyn Bosch, Godspower Akpomiemie, Angela Tembo et al. · 2023 · Frontiers in Reproductive Health
93. Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide (TAF) in People With Human Immunodeficiency Virus (HIV)
    José Damas, Aline Munting, Jacques Fellay, David Haerry, Catia Marzolini, PHILIP E. TARR, Ana Steffen, Dominique L. Braun, Marcel P. Stoeckle, Enos Bernasconi et al. · 2024 · Clinical Infectious Diseases
94. Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and Zambia
    Veronika Whitesell Skrivankova, Jacqueline Madalitso Huwa, Guy K. Muula, Geldert Davie Chiwaya, Esau Banda, Shameem Buleya, Belinda Chihota, Joseph Chintedza, Carolyn Bolton‐Moore, Hannock M. Tweya et al. · 2024 · Clinical Infectious Diseases
95. An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus
    Wing Sun Chow, Prina Z Donga, Aurélie Côté‐Sergent, Carmine Rossi, Patrick Lefèbvre, Marie‐Hélène Lafeuille, Bruno Émond, Hélène Hardy · 2020 · Current Medical Research and Opinion
96. First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines
    Kate El Bouzidi, Sophie José, Andrew N. Phillips, Anton Pozniak, Andrew Ustianowski, Mark M Gompels, Alan Winston, Ab Schaap, David T. Dunn, Caroline Anne Sabin · 2020 · AIDS
97. Weight gain in HIV-infected individuals using distinct antiretroviral drugs
    Luís Buzón · 2020 · Aids Reviews
98. Non-communicable Diseases in Pregnant and Postpartum Women Living with HIV: Implications for Health Throughout the Life Course
    Risa M. Hoffman, Caitlin N. Newhouse, Brian Chu, Jeffrey S. A. Stringer, Judith S. Currier · 2021 · Current HIV/AIDS Reports
99. Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade
    Lucia Taramasso, Paolo Bonfanti, Elena Delfina Ricci, Paolo Maggi, Giancarlo Orofino, Nicola Squillace, Barbara Menzaghi, Giordano Madeddu, Chiara Molteni, Francesca Vichi et al. · 2021 · HIV Medicine
100. Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug
     Nikos Pantazis, Vasilios Papastamopoulos, Anastasia Antoniadou, Georgios Adamis, Vasilios Paparizos, Symeon Metallidis, Helen Sambatakou, Mina Psichοgiou, Maria Chini, Georgios Chrysos et al. · 2022 · Viruses